Diversity in changes of HRQoL over a 1-year period after radiotherapy in Norwegian breast cancer patients: results of cluster analyses.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Jun 2019
Historique:
accepted: 30 01 2019
pubmed: 8 2 2019
medline: 25 7 2019
entrez: 8 2 2019
Statut: ppublish

Résumé

The diversity in long-term changes in health-related quality of life (HRQoL) among breast cancer (BC) survivors is poorly understood. The aim of this study was to identify clusters of trajectories (subgroups of patients with similar patterns of changes) of selected HRQoL domains over a 1-year period after radiotherapy (RT) in BC patients. The group consisted of 250 BC patients referred for postoperative RT. Global quality of life (QoL), functions, and cancer-specific symptoms were assessed using the European Organisation for Research and Treatment of Cancer (EORTC) core Quality of Life Questionnaire (QLQ-C30) before starting RT, at completion of RT and 3, 6, and 12 months after RT. A hierarchical cluster analysis was used to identify possible trajectories of HRQoL domains. Three distinct types of clusters of trajectories were identified for all outcome variables: Type 1 clusters encompassing the rather time-stable high-global QoL cluster, high-functioning clusters, and low-symptom clusters (44-98% of patients), Type 2 clusters with medium levels of HRQoL domains (8-49%), Type 3 clusters encompassing low-global QoL, low-functioning, and high-symptoms clusters (2-51%). Our results demonstrated a noticeable heterogeneity of changes in HRQoL domains after BC treatment. The findings support the importance of an accurate patient-reported HRQoL assessment as a routine element of BC survivors' care. The pre-RT assessment of HRQoL alone allows to predict the course of HRQoL changes over the 1-year period after RT and the risk of "falling into" low functioning clusters.

Identifiants

pubmed: 30729449
doi: 10.1007/s11136-019-02127-7
pii: 10.1007/s11136-019-02127-7
pmc: PMC6522443
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1521-1530

Subventions

Organisme : Norges Teknisk-Naturvitenskapelige Universitet
ID : 82403726

Références

Breast Cancer Res Treat. 2007 Jun;103(2):185-95
pubmed: 17039266
Breast Cancer Res Treat. 2007 Oct;105(2):209-19
pubmed: 17203386
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):795-803
pubmed: 20888704
Acta Oncol. 2011 Feb;50(2):187-93
pubmed: 21231780
Health Technol Assess. 2011 Mar;15(12):i-xi, 1-57
pubmed: 21366974
Gynecol Oncol. 2012 Apr;125(1):59-64
pubmed: 22155797
Cancer. 2012 Apr 15;118(8 Suppl):2217-25
pubmed: 22488696
Brain Behav Immun. 2012 Aug;26(6):830-48
pubmed: 22595751
Behav Sleep Med. 2013;11(3):189-206
pubmed: 23205513
Acta Oncol. 2013 Feb;52(2):239-48
pubmed: 23210971
J Cancer Surviv. 2013 Mar;7(1):20-31
pubmed: 23232922
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Acta Oncol. 2013 Aug;52(6):1119-28
pubmed: 23514583
Breast. 2013 Oct;22(5):952-7
pubmed: 23751861
J Pain Symptom Manage. 2014 Apr;47(4):731-41
pubmed: 23916827
J Clin Oncol. 2013 Oct 1;31(28):3540-8
pubmed: 23980087
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1043-50
pubmed: 24161428
Psychooncology. 2014 Sep;23(9):1014-20
pubmed: 24700668
Cancer Nurs. 2015 Jan-Feb;38(1):E29-54
pubmed: 24831042
Breast. 2014 Oct;23(5):609-16
pubmed: 25034932
Support Care Cancer. 2016 Jan;24(1):243-251
pubmed: 26014617
Br J Surg. 2016 Apr;103(5):524-36
pubmed: 26924354
Ann Oncol. 2016 Jun;27(6):965-74
pubmed: 26940687
Acta Oncol. 2016 Jun;55(6):720-7
pubmed: 26942569
Clin Ther. 2016 Apr;38(4):821-30
pubmed: 27045992
Scand J Occup Ther. 2018 Jul;25(4):298-307
pubmed: 28562163
Health Qual Life Outcomes. 2018 Jun 4;16(1):114
pubmed: 29866185
JMIR Hum Factors. 2018 Jul 16;5(3):e10070
pubmed: 30012546
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735

Auteurs

Magdalena Anna Lazarewicz (MA)

Department of Medical Psychology and Medical Communication, Medical University of Warsaw, Warsaw, Poland.

Dorota Wlodarczyk (D)

Department of Medical Psychology and Medical Communication, Medical University of Warsaw, Warsaw, Poland.

Steinar Lundgren (S)

Department of Oncology, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Randi Johansen Reidunsdatter (RJ)

Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. randi.j.reidunsdatter@ntnu.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH